N
NIMGenetics
An analytical Diagnosis Center with a Genetics unit authorized by the Department of Health of the Community of Madrid
About NIMGenetics
NIMGenetics operates as a specialized analytical diagnostic center with a dedicated genetics unit, officially authorized by the Health Council of the Community of Madrid since 2009. The company was founded by Dr. Enrique Samper and Javier Pérez. Dr. Samper, who holds a PhD in Biological Sciences and has an extensive background in researching telomeres, cellular aging, and cancer at prestigious institutions like the Cold Spring Harbor Laboratory and the Spanish National Cancer Research Centre (CNIO), serves as the scientific lead. Javier Pérez, a partner, likely complements this with business or operational expertise.
Read full description
The firm focuses on the development and application of high-resolution genomic systems to provide precise clinical diagnostics. Its core business involves offering advanced genomic tools to medical professionals, aiming to enhance healthcare in areas like prevention, prognostic characterization, and diagnostic reliability. A key product is KaryoNIM®, a genomic tool that helps identify copy number variations in DNA that have phenotypic repercussions. Since 2008, the company has received support from the Centre for the Development of Industrial Technology (CDTI), which has bolstered its innovation capacity.
NIMGenetics serves a client base that includes over 50 diagnostic centers, clinics, and hospitals. Beyond its clinical diagnostic services, the company also caters to researchers and research services. For this segment, it provides a wide array of genomic tools coupled with personalized support that spans from experimental design and platform selection to comprehensive bioinformatic analysis. This dual focus on both clinical and research applications positions the company as a key player in the Spanish genetics and genomics market.
At a glance
- Founded
- 2008
- Headquarters
- Madrid, Spain
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Apposite Capital
Series B and later1 investor entered at this stage
ENISA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NIMGenetics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NIMGenetics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.